| 2.11 0.39 (22.67%) | 09-01 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.51  |
1-year : | 2.93 |
| Resists | First : | 2.15 |
Second : | 2.51 |
| Pivot price | 1.35 |
|||
| Supports | First : | 1.2 |
Second : | 0.62 |
| MAs | MA(5) : | 1.63 |
MA(20) : | 1.25 |
| MA(100) : | 1.07 |
MA(250) : | 4.56  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 90.3 |
D(3) : | 89.3 |
| RSI | RSI(14): 83.7 |
|||
| 52-week | High : | 12.39 | Low : | 0.62 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ FBLG ] has closed above the upper band by 19.1%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 62.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.15 - 2.16 | 2.16 - 2.17 |
| Low: | 1.7 - 1.71 | 1.71 - 1.72 |
| Close: | 2.1 - 2.11 | 2.11 - 2.12 |
FibroBiologics, Inc. operates as a clinical-stage biopharmaceutical firm, advancing therapies derived from fibroblasts toward commercialization within the United States. The company's pipeline includes CybroCell, currently being developed to address degenerative disc disease; CYMS101, targeting multiple sclerosis; and CYWC628 for wound repair. Further demonstrating its broad scope, early-stage investigations are underway for CYTER915, aimed at restoring or enhancing thymus and/or spleen function; CYPS317, for psoriasis; and TCB190, designed to combat specific cancers. FibroBiologics was founded in 2021 and is situated in Houston, Texas.
Fri, 14 Aug 2026
Armistice Capital discloses 9.99% FibroBiologics (FBLG) stake via Master Fund - Stock Titan
Fri, 24 Jul 2026
FibroBiologics (NASDAQ: FBLG) appeals Nasdaq move to delist its shares - Stock Titan
Mon, 29 Jun 2026
FibroBiologics secures $3M now, with $6M more tied to warrants - Stock Titan
Fri, 26 Jun 2026
FBLG Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 26 Jun 2026
FibroBiologics raises $3M now, with $6M more possible if warrants are exercised - Stock Titan
Wed, 01 Apr 2026
FibroBiologics, Inc. Announces Pricing of Public Offering for 2.27 Million Shares and Warrants - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 15.5 (%) |
| Shares Short | 115 (K) |
| Shares Short P.Month | 136 (K) |
| EPS | -5.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -95.8 % |
| Return on Equity (ttm) | -660.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -15 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 2.77 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|